Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer,
Brief Summary:
Ovarian cancer is a leading cause of cancer death in women. Monocytes are white blood cells that slow tumor growth. Interferons (IFNs) are molecules that help immune cells fight cancer. Researchers want to stimulate monocytes with IFNs. They want to test if these stimulated monocytes combined with the drugs Sylatron and Actimmune can shrink tumors and slow the progression of cancer.
Objective:
To test how well IFN stimulated monocytes, with Sylatron and Actimmune, kill tumor cells.
Eligibility:
Women ages 18 and older with certain ovarian, fallopian tube, or peritoneal cancers
Design:
Participants will be screened with:
Medical history
Physical exam
Blood and urine tests
Scan
Results or sample from previous biopsy
Participants may have a tumor sample taken.
Participants who do not have a port will have a catheter placed inside the abdominal cavity. It will be used to give the treatment.
Participants will have visits for 4 days of each 28-day cycle. This includes overnight observation.
Participants with ascites fluid in their abdominal cavity will have it sampled twice.
Each cycle, participants will have: